PCN79 The Cost-Effectiveness Of Companion Diagnostics In Cancer Therapy  by Mathurin, K. et al.
A142 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 1 - A 2 9 8  
  
 
bendamustine is a cost-effective strategy in the treatment of rituximab-
refractory iNHL.  
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OBJECTIVES: The identification of potential biomarkers in oncology have led to 
the development of companion diagnostics to better select cancer treatment and 
consequently, to increase success rates and potentially reduce costs. The 
objective of this study was to explore the existing evidences regarding the cost-
effectiveness of companion diagnostics in cancer therapy. METHODS: An 
exhaustive literature search previously performed using 4 electronic databases 
from January 1967 until December 2012 allowed retrieving 15,374 studies. Among 
them, 19 studies assessed the economic impact of a companion diagnostic to 
guide therapy or to predict treatment-related toxicity compared with the “no 
testing” strategy. Cost-effectiveness ratios and study parameters were extracted 
from these studies and costs were reported in US$2012. RESULTS: Breast cancer 
was the main indication of the companion diagnostics evaluated. Cost-utility 
analyses (cost per QALY) were performed in 79% of studies. Other studies 
reported results as a cost per case or a cost per life-year gained. Cost of 
companion diagnostic was comprised between $US57 and $US4,469. Cost-
effectiveness ratios of companion diagnostics varied from dominant to 
approximately $US162,000 per QALY. Specifically, using a $50,000 per QALY 
threshold, 9 studies suggested that companion diagnostics are cost-effective or 
could be cost-effective in specific conditions. Furthermore, few companion 
diagnostics were dominated by the “no testing” strategy, depending on the 
method of testing used. In addition, two studies have established a maximum 
cost for the companion diagnostic to be cost-effective. CONCLUSIONS: Most of 
analyzed studies suggest that companion diagnostics are or could be cost-
effective in specific conditions, despite a wide cost-effectiveness ratios range. 
Ratios obtained mainly depend on cancer type, method of testing and cost of 
companion diagnostic.  
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OBJECTIVES: The use of a companion diagnostic to identify subgroups of 
patients most likely to respond to a cancer therapy or to avoid treatment-related 
toxicities can increase success rates of oncology drugs and potentially reduce 
overall treatment costs. The objective of this study was to explore the existing 
evidences regarding economic evaluations of companion diagnostics in cancer 
therapy. METHODS: A structured exhaustive literature search was performed 
using electronic databases from January 1967 until December 2012 to identify 
economic evaluations of companion diagnostics in cancer therapy. Titles were 
initially screened for relevance. Then, abstracts of potentially relevant studies 
were reviewed. Finally, full-text articles were obtained for studies deemed 
relevant according to the abstract and were analyzed in details and relevant 
characteristics were extracted. RESULTS: The literature search allowed retrieving 
15,374 studies. A quick screening of titles allowed excluding 14,014 studies. 
Among the 1,359 abstracts remaining, 235 were economic studies. While the 
large majority of these economic studies evaluated cancer treatment and 
screening cancer methods, 21 were using a companion diagnostic to predict 
treatment response or treatment-related toxicity. Breast cancer was the main 
indication of the companion diagnostics evaluated (57%). Other indications were 
colorectal, leukemia, lung and gastrointestinal tract cancers. Almost all of the 
companion diagnostics evaluated (86%) aimed guiding the choice of the 
treatment and predicting treatment response. A large majority of the economic 
evaluations was model-based studies, with an equal proportion of Markov model 
and decision tree. Cost-utility (cost per QALY) analyses accounted for 57% of 
studies. Approximately 52% adopted a lifetime horizon and 62% used a health 
care system perspective. CONCLUSIONS: Although several companion 
diagnostics have been recently developed, only few of them have been 
economically evaluated in limited cancer types. While choice of methodology 
slightly varies, a relative uniformity in study parameters has been observed 
among economic evaluations.  
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OBJECTIVES: The Centers for Disease Control and Prevention’s Screen for Life: 
National Colorectal Cancer Action Campaign (SFL) is one of the longest-running 
national multimedia campaigns to promote colorectal cancer (CRC) screening for 
men and women aged ≥50 in the United States. Since inception in 1999, no study 
has quantified the benefits and costs of the SFL campaign. METHODS: We 
modeled the impact of the SFL campaign using a range of effect sizes obtained 
from prior studies on the impact of public health mass media campaigns. We 
assumed that the effect size (i.e. the proportion of persons exposed to the 
campaign who are screened as a result of the campaign) would range from 0.5% 
to 10% of unscreened population exposed to the campaign in the last 14 years 
(1999–2012). Using the assumed effect size and other data obtained from the 
literature, we estimated the benefits of the campaign defined as the incremental 
population screened from being exposed to campaign messages. Given the 
estimated benefits of the campaign and costs, we calculated cost per person 
screened (2012 US dollars). RESULTS: If 0.5% of the population exposed to 
campaign messages were screened as a result of the exposure, an additional 
251,000 persons would have been screened from 1999-2012. The average annual 
cost per person screened was $2.44. If the effect size was 10%, an additional 5.01 
million persons would have received screening during this time period as a 
result of the campaign. The average annual cost per person screened was $0.12. 
CONCLUSIONS: The results from this exploratory study indicate that the SFL 
campaign may have contributed to improving CRC screening rates at a minimal 
cost. Our methods provide a model for analyzing the benefits and costs of mass 
media health promotion campaigns when no outcome data are available.  
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OBJECTIVES: Lung cancer remains the leading cause of cancer death in Canada 
and worldwide. Non-small cell lung cancer (NSCLC) accounts for 85% of all lung 
cancers. Conventional treatments of NSCLC have reached the upper bound of 
effectiveness in improving survival and treatment outcomes must still be 
considered disappointing. Recent achievements have been made in the 
understanding of the molecular biology of lung cancer targeted therapies and the 
discovery of new targets, such as the EML4–ALK fusion gene. Targeted therapy 
with ALK inhibitor crizotinib offers significant improvement in clinical outcome 
for treatment of EML4–ALK fusion positive patients. We estimated the cost-
effectiveness of companion EML4-ALK genetic testing in combination with 
crizotinib for NSCLC in Ontario. METHODS: We performed a cost-effectiveness 
analysis using a Markov model from a Ministry of Health perspective and a 
lifetime horizon. Transition probabilities and mortality rates were calculated 
based on the data of 8,113 patients obtained from the Cancer Care Ontario New 
Drug Funding Program database for 2005-2009. Costs were obtained from OCCI 
database, public labs and Princess Margaret Hospital. RESULTS: Our preliminary 
results show that genetic testing and treatment combination strategy gained 0.11 
QALYs when compared to no testing. The incremental cost was CAD $4,320 
compared to standard care, and the incremental cost-effectiveness ratio for the 
base case was $385,438 per QALY. CONCLUSIONS: EML4–ALK genetic testing in 
combination with crizotinib treatment for all NSCLC patients eligible for 
chemotherapy is not economically attractive in the current setting. Lower drug 
costs would be required to make this strategy economically attractive at 
conventional cost effectiveness thresholds  
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OBJECTIVES: Multiple endocrine neoplasia type 2B (MEN2B) is a genetic disease 
that causes multiple tumors on the mouth, eyes, and endocrine glands. The 
prevalence of MEN2B is estimated to be 1 in 600,000 and leads to aggressive, 
usually incurable, medullary thyroid cancer usually during adolescents. MEN2B 
status can be identified by genetic screening and curative thyroidectomy surgery 
offered. Despite the clear benefits MEN2B testing is not part of routine clinical 
management in Australia. The aim of this study is to evaluate the cost-
effectiveness of applying different MEN2B genetic screening strategies in 
Australia. METHODS: A decision analytical model was constructed to evaluate 
cost per quality-adjusted life-year, life-years gained and case detected by 
comparing three competing strategies: 1) no MEN2B testing, 2) screening every 
newborn baby and 3) screening only patients that attend Marfan’s clinics (it is 
estimated that 85% of the MEN2B carriers express Marfanoid habitus, and 
consequently will be tested for Marfan syndrome). The impact of uncertainty 
was evaluated using probabilistic sensitivity analysis. RESULTS: Current practice 
(No MEN2B testing) is dominated by providing MEN2B testing at Marfan’s clinics; 
this is because the cost of screening is more than offset by the cost of cancer 
treatment avoided. When comparing newborn screening (population based 
screening) to providing MEN2B testing at Marfan’s clinics, the incremental cost-
effectiveness ratio (ICER) is $8,669 per QALY gained. The cost per case detected is 
$36,235 when providing gene testing at Marfan’s clinics and $407,200 in the 
newborn screening strategy. Prevalence of MEN2B and the cost of MEN2B testing 
in Newborn screening are important parameters. CONCLUSIONS: Genetic 
screening on an individual’s risk of cancer is an appealing prospect. We 
demonstrated that performing MEN2B testing at Marfan’s clinics is likely to be 
cost-saving, compared to current practice. Whilst screening all newborn babies 
may also be a cost-effective option.  
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